Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

Giulio Draetta, former MD Anderson CSO, center director joins privately held Orionis Biosciences

Giulio Draetta was recently named chief strategy officer at Orionis Biosciences, a privately held, clinical stage life sciences company focused on discovery, design, and development of precision medicines for cancer and immune system-related disorders. Orionis is based in Boston and Ghent, Belgium.

May 29, 2026

Vol.52 No.21

In Brief

Albert Koong named chief scientific officer at MD Anderson

Albert Koong was appointed chief scientific officer at the University of Texas MD Anderson Cancer Center effective June 1.

May 22, 2026

Vol.52 No.20

In Brief

MD Anderson establishes Center for Cellular Language Intelligence with $10M gift

The University of Texas MD Anderson Cancer Center announced a $10 million gift from Peggy and Carl Sewell to establish the Center for Cellular Language Intelligence, a research center created to understand the behavior of cancer cells at a high resolution, potentially enabling earlier cancer detection, smarter prevention, and more precise, personalized treatments.

May 01, 2026

Vol.52 No.17

In Brief

UT Austin announces first tech-native academic medical center in the U.S.

The University of Texas at Austin is building an integrated academic medical center from the ground up, where care, research, and education operate as one system organized around the patient. This model connects prevention, diagnosis, treatment, and long-term health into a continuous experience, particularly for those with complex and serious conditions.

April 24, 2026

Vol.52 No.16

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

Researchers from The University of Texas MD Anderson Cancer Center have found that simultaneously blocking two key “don’t eat me” signals found in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in models of glioblastoma, highlighting a promising strategy.

March 27, 2026

Vol.52 No.12

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

YOU MAY BE INTERESTED IN

Giulio Draetta, former MD Anderson CSO, center director joins privately held Orionis Biosciences

Albert Koong named chief scientific officer at MD Anderson

MD Anderson establishes Center for Cellular Language Intelligence with $10M gift

UT Austin announces first tech-native academic medical center in the U.S.

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

Renew today!

Subscriber content

Never miss an issue!

Login